Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

Weinstock‐Guttman, Bianca; Zivadinov, Robert; Horáková, Dana; Havrdová, Eva; Qu, Jun; Shyh, Grace; Lakota, Elizabeth A; O’Connor, Kerri; Badgett, Darlene; Tamaño‐Blanco, Miriam; Týblová, Michaela; Hussein, Sara; Bergsland, Niels; Willis, Laura; Krásenský, Jan; Vaněčková, Manuela; Seidl, Zdeněk; Ramanathan, Murali

doi:10.1136/jnnp-2012-304740

Cited by 118 publications

(114 citation statements)

References 39 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…One possible explanation for this discrepancy is the presence of age-related vascular lesions without central veins. This finding, which remains to be confirmed, supports the contribution of comorbidities to the brain lesion load in patients with MS 36,37 . To date, no imaging studies have been performed on the venocentric distribution of brain lesions in paediatric MS. Susac syndrome.…”

Section: The Central Vein In Ms Discussionsupporting

confidence: 66%

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

et al. 2016

Self Cite

View full text Add to dashboard Cite

At present, the diagnosis of multiple sclerosis (MS) relies heavily on the use of MRI, which can demonstrate disease dissemination in space and time [1][2][3][4] . The current 2010 McDonald criteria have enabled earlier diagnosis 5,6 and initiation of disease-modifying treatment, with substantial benefits for disease outcome 7,8 , but they still have imperfect sensitivity and specificity 9,10 . The limited accuracy of the criteria results in challenging cases and misdiagnosis, which are prevalent problems in MS 11,12 . Therefore, more-accurate and pathologically specific MRI criteria are still needed to exclude other disorders that can mimic MS 13,14 .The MRI-detectable central vein inside white matter lesions has recently been proposed as a biomarker of inflammatory demyelination and, thus, may aid the diagnosis of MS 15 . The 'central vein sign' (CVS) has been investigated in various neurological conditions by several groups, and evidence has accumulated that the CVS may have the ability to accurately differentiate MS from its mimics [15][16][17][18][19][20][21] . As a consequence, recent guidelines from the Magnetic Resonance Imaging in MS (MAGNIMS) group 1,4 and the Consortium of MS Centers (CMSC) task force 22 have acknowledged the potential of the CVS and its dedicated MRI acquisitions for the differential diagnosis of MS, while calling for further research before considering a possible modification of the diagnostic criteria. However, the lack of standardization for the definition and imaging of the CVS, as well as a dearth of large-scale prospective studies evaluating the CVS for MS diagnosis, are currently preventing the clinical validation of this potential biomarker 1,23 .This Consensus Statement aims to provide recommendations for the definition, standardization and clinical evaluation of the CVS in the diagnosis of MS. These statements are based on a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative. E X P E RT C O N S E N S U S D O C U M E N T on behalf of the NAIMS CooperativeAbstract | Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Mult...

show abstract

Section: The Central Vein In Ms Discussionsupporting

confidence: 66%

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…We found that each 10 mg/dl of greater baseline LDL cholesterol (LDL-C), total cholesterol (TC), and apoB was associated with a 7.4%, 5.9%, and 16% increase in the number of new T2 lesions over 2 years of IFN- treatment, respectively (22,23). Our findings on cholesterol and apolipoproteins in MS disease progression have since been independently confirmed (24)(25)(26).…”

Section: Discussionmentioning

confidence: 58%

“…In this report, we investigated the effects of long-term IFN-1a treatment on cholesterol profiles following the first demyelinating event in patients enrolled in the SET study (23,(29)(30)(31). IFN- treatment was associated with an IFN- remains an important first-line MS therapy alongside glatiramer acetate.…”

Section: Discussionmentioning

confidence: 99%

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients

Uher

Fellows

Horáková

et al. 2017

Journal of Lipid Research

Self Cite

View full text Add to dashboard Cite

Interferon- (IFN-) treatment is one of the most widely used disease-modifying treatments for multiple sclerosis (MS). The efficacy of recombinant human IFN- for relapsing MS has been established by multiple double-blind placebo-controlled multi-center trials (1-3). IFN- can delay the conversion to clinically definite MS (CDMS) in patients with a first demyelinating event (4-6), which supports early intervention with IFN-.MRI atrophy measures of brain volume and gray matter, white matter, and lateral ventricle volumes provide quantitative measures of global and tissue-specific brain volumes (7-9). Brain atrophy is useful for evaluating disease progression and therapeutic efficacy in MS (7) because it is a predictor of physical disability, cognitive dysfunction, and quality of life (10). However, there is a lack of effective serum biomarkers capable of predicting atrophy in MS patients.There is considerable inter-individual variability of IFN1a effectiveness among MS patients. Phase III studies of IFN- indicate a 30-40% general clinical benefit, although the response varies significantly among MS patients. On MRI, approximately 40% of patients show complete suppression of new contrast-enhancing lesions (CELs), whereas 20% of patients have less than 70% suppression

show abstract

“…Comorbidities linked to dyslipidemia were reported to be associated with increased risk for MS disability progression [8,10]. It has been reported that lipids and Lp-PLA2 activity has modest effects on MS [8,[10][11][12]. However the data in this field is limited to reach an exact conclusion.…”

Section: Introductionmentioning

confidence: 72%

“…The differences among studies are likely to depending on the genetic, environmental and nutritional factors. The study made by Weinstock et al [12] showed that no associations of LDL-C and total cholesterol with disability changes in patients with high risk clinically isolated syndromes after the first demyelinating event. It was also reported that lipid metabolism in the CNS is regulated independently and almost all cholesterol present in total cholesterol, triglyceride, HDL-C, LDL-C, AIP, non-HDL-C and TCHOL/ HDL-C concentrations between patients and healthy control group.…”

Section: Introductionmentioning

confidence: 99%

SERUM LIPIDS AND Lp-PLA2 ACTIVITY IN MULTIPLE SCLEROSIS

Doğan¹

2014

Turk J Bioch

View full text Add to dashboard Cite

Objective: Multiple sclerosis (MS) is an inflammatory demyelinating disease arising from unknown origin. Dyslipidemia, T-lymphocyte mediated inflammation, lipoprotein associated oxidative activity and lipoprotein associated phospholipase A2 (Lp-PLA2) activity include the pathogenesis of MS. In the current study, we evaluated the effect of Lp-PLA2 activity and serum lipids in MS patients with different clinical stages to understand the effect these parameters on MS progression.

show abstract

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

Abstract: In early multiple sclerosis, lipid profile variables particularly LDL-C and TC levels are associated with inflammatory MRI activity measures.

Cited by 118 publications

References 39 publications

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients

SERUM LIPIDS AND Lp-PLA2 ACTIVITY IN MULTIPLE SCLEROSIS

Contact Info

Product

Resources

About